RNA Clinical Trials Resources

  1. Shifting The Approach: 4 Strategies For ICH E6(R3) Implementation 4/30/2024

    In addition to codifying some best practices, R3 suggests sponsors take a proportionate approach to identifying and managing areas of risk.

  2. Advantages Of Cas9 mRNA For Gene Editing 4/26/2024

    Discover why Cas9 mRNA is the preferred choice for precise gene editing, offering efficient delivery, transient expression, and flexible targeting.

  3. A New Era For Patient Recruitment And Retention In Rare Disease 3/15/2024

    Pharma and biotech companies prioritize innovation in areas of high and rare unmet need. Though the R&D landscape for these rare diseases can be difficult to navigate, changes are on the horizon.

  4. CRISPR Clinical Trials To Follow In 2024 And Beyond 3/13/2024

    CRISPR therapies are being developed for genetic disorders, cancer, and infectious diseases. Explore which CRISPR clinical trials are worth keeping an eye on this year.

  5. Precision Oncology Clinical Trials And Statistics 2024 3/12/2024

    Delve into the latest advancements in clinical trials, targeted therapies, and the promising horizon of cancer care.

  6. Global Prevalence And Clinical Trials Landscape Of DMD 3/11/2024

    Stay informed with the latest advancements in the fight against Duchenne Muscular Dystrophy, a disease that impacts thousands of lives worldwide.

  7. Discussing mRNA: Challenges And Opportunities For Scale-Out And Optimization 2/6/2024

    In a recent Cell & Gene Live event, experts explored challenges surrounding raw materials – both quality and supply – as well as the importance of achieving more efficient scale-out and turnaround times for mRNA production.

  8. Uncovering Hidden CRO Contract Costs Before Signing A Contract 1/22/2024

    Navigating the complex landscape of clinical trials can be challenging. Utilize this reliable CRO Checklist to empower teams to stay ahead and safeguard every trial's budget effectively.

  9. The Future Of mRNA For Cancer Treatment 1/9/2024

    As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS.

  10. Accelerated Development: Gene Therapy Vs. Small Molecule 12/26/2023

    Combined with the inherent difficulty of the chemistry behind gene therapy development, its pace, structure, and funding dynamics are unique among treatment modalities.